USPTO Examiner FUBARA BLESSING M - Art Unit 1613

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18977228Ribociclib TabletDecember 2024June 2025Allow730NoNo
18829557NOVEL LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOFSeptember 2024April 2025Allow710YesNo
18786785METHOD FOR HYPERTHERMIALLY TREATING A CANCERJuly 2024October 2024Allow210NoNo
18632164PAINLESS NGF FOR FRACTURE REPAIRApril 2024May 2025Abandon1310NoNo
18603884TAMPER RESISTANT DOSAGE FORMSMarch 2024July 2024Allow430NoNo
18599893HIGH STEROL-CONTAINING LIPID NANOPARTICLESMarch 2024April 2025Allow1320YesNo
18681556PREPARATION OF COMPOSITE GELS, POLYMER SCAFFOLDS, AGGREGATES AND FILMS COMPRISING SOLUBLE CROSS-LINKED CHITOSAN & USES THEREOFFebruary 2024May 2025Allow1521YesNo
18431035PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCERFebruary 2024April 2025Allow1410NoNo
18395521IMPLANTABLE POLYMER FOR BONE AND VASCULAR LESIONSDecember 2023March 2025Abandon1410NoNo
18531424HETEROCYCLIC COMPOUNDS AND THEIR USESDecember 2023December 2024Allow1210NoNo
18512499CANCER TREATMENT METHOD FOR MAGNETIC HYPOTHERMIA CANCER TREATMENTNovember 2023July 2024Allow810NoNo
18475755TAMPER RESISTANT DOSAGE FORMSSeptember 2023March 2024Allow510NoNo
18372560Multiple Unit Dosage Form Having A Therapeutic Agent In Combination With A Nutritional SupplementSeptember 2023December 2024Allow1520NoNo
18459805POLYCAPROLACTONE-BASED FIBERS AND IMPLANTS INCLUDING SAMESeptember 2023November 2024Allow1520YesNo
18450842METHOD FOR TREATING BREAST CANCERAugust 2023November 2023Allow310NoNo
18337570COSMETIC COMPOSITIONS CAPABLE OF FORMING A MULTILAYER STRUCTURE AFTER APPLICATION TO A KERATINOUS MATERIALJune 2023August 2024Allow1420YesNo
18205786TAMPER RESISTANT DOSAGE FORMSJune 2023December 2023Allow610YesNo
18204233Polyphosphate-Functionalized Inorganic Nanoparticles as Hemostatic Compositions and Methods of UseMay 2023November 2024Allow1820YesNo
18143927TAMPER RESISTANT DOSAGE FORMSMay 2023September 2023Allow510YesNo
18298623TRANSDERMAL DELIVERY SYSTEM WITH A MICROPOROUS MEMBRANE HAVING SOLVENT-FILLEDPORESApril 2023May 2025Abandon2530NoNo
18187904HIGH STEROL-CONTAINING LIPID NANOPARTICLESMarch 2023December 2023Allow911YesNo
18184816IMPLANTABLE MEDICAL DEVICE WITH THERMOPLASTIC COMPOSITE BODY AND METHOD FOR FORMING THERMOPLASTIC COMPOSITE BODYMarch 2023December 2023Allow920NoNo
18117315HYDRATION COMPOSITIONSMarch 2023November 2024Allow2110YesNo
18115854HEARTWORM MEDICAMENTMarch 2023August 2023Allow610NoNo
18174674DRY POWDER FORMULATIONS FOR INHALATIONFebruary 2023July 2024Allow1620NoNo
18099953FORMULATIONS WITH COLLOIDAL SILVERJanuary 2023November 2024Allow2220NoNo
18152965TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING A SILICONE POLYMERJanuary 2023July 2024Allow1920YesNo
18095329SELF-LUBRICATING MEDICAL ARTICLESJanuary 2023January 2025Allow2440NoNo
18148724Oral Care CompositionsDecember 2022March 2024Allow1420YesNo
18146736Core-Shell Microcapsule with a Polyamine-Based Thermosetting ShellDecember 2022May 2024Allow1620YesNo
18083774SUSTAINED DELIVERY FORMULATIONS OF RISPERIDONE COMPOUNDDecember 2022November 2024Abandon2320NoNo
18072772TREATMENT OF IMMUNE DISEASES BY ADMINISTRATION OF ANTIGEN-SPECIFIC FORMULATIONSDecember 2022November 2023Allow1110NoNo
17985757SYSTEMS AND METHODS FOR BLENDING SOLID-SHELL COSMETIC INGREDIENT CAPSULES AND BLENDABLE COSMETIC INGREDIENT CAPSULESNovember 2022February 2024Allow1510NoNo
17977902GELLING MULTIPARTICULATESOctober 2022March 2024Allow1710NoNo
17971025COMPOSITIONS AND METHODS FOR TREATMENT OF SYMPTOMS IN PARKINSON'S DISEASE PATIENTSOctober 2022April 2024Allow1810YesNo
17954279Compositions for Inhibition of Insect SensingSeptember 2022March 2025Abandon2901NoNo
17934737COSMETIC COMPOSITIONS CAPABLE OF FORMING A MULTILAYER STRUCTURE AFTER APPLICATION TO A KERATINOUS MATERIALSeptember 2022March 2023Allow510NoNo
17802984PROTEIN PRODUCT CAPABLE OF IMMOBILIZING TARGET AND BEING CLEARED AS REQUIREDAugust 2022February 2025Allow2900YesNo
17892553TAMPER RESISTANT DOSAGE FORMSAugust 2022December 2023Allow1610YesNo
17818687POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTSAugust 2022September 2024Abandon2611NoNo
17880175OCULAR HYDROGEL TYROSINE KINASE INHIBITOR IMPLANTSAugust 2022August 2024Abandon2410NoYes
17877542PREPARATION CONTAINING TETRACYCLIC COMPOUND AT HIGH DOSEJuly 2022January 2024Abandon1810NoNo
17873968METHODS OF TREATING PATIENTS AT RISK FOR RENAL INJURY AND RENAL FAILUREJuly 2022December 2023Allow1710NoNo
17856682COMPOSITIONS AND RESULTING HARD CAPSULES COMPRISING HYDROPHILIC COLORING FOODSTUFF CONCENTRATESJuly 2022December 2023Allow1820NoNo
17810274SHAPE MEMORY ADHESIVES FOR APPAREL PRODUCTSJune 2022July 2023Allow1221YesNo
17806033HETEROCYCLIC COMPOUNDS AND THEIR USESJune 2022September 2023Allow1510NoNo
17805956Ribociclib TabletJune 2022December 2023Allow1810NoNo
17835739NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERINGJune 2022June 2025Allow3731YesNo
17827504NATURAL COMPOSITION FOR USE IN GYNAECOLOGYMay 2022October 2023Allow1720NoNo
17824425TOPICAL COMPOSITION AND METHOD OF USEMay 2022August 2024Allow2711NoNo
17752813Scaffold for Regenerative Organization of Prosthetic Organ Tissue and MethodMay 2022March 2024Abandon2221YesNo
17721183METHOD OF TREATING EPILEPSYApril 2022June 2024Allow2640YesNo
17712618Method and Apparatus for Treating Bone Fractures, and/or for Fortifying and/or Augmenting Bone, Including the Provision and Use of Composite ImplantsApril 2022October 2023Abandon1910NoNo
17699919HEMOSTATIC PASTE AND METHODS OF MAKING THEREOFMarch 2022March 2023Allow1220NoNo
17691299Capsule to support the body's defense against microplasticsMarch 2022January 2024Abandon2310NoNo
17641056ONIUM SALT OF NITROGEN-CONTAINING HETEROARYL COMPOUND AND PEST CONTROL AGENTMarch 2022June 2025Allow4011YesNo
17686827Multiple Unit Dosage Form Having A Therapeutic Agent In Combination With A Nutritional SupplementMarch 2022September 2023Allow1840YesNo
17639932AQUEOUS CONDITIONER FORMULATION FOR THERMALLY STYLED HAIRMarch 2022March 2025Allow3610YesNo
17680646Polyurethane Based Medical ArticlesFebruary 2022July 2024Allow2921NoNo
17631775METHOD FOR TREATING KERATIN MATERIAL, COMPRISING THE USE OF AN ORGANIC C1-C6-ALKOXY-SILANE AND AN AMINO ACID AND/OR AN AMINO ACID DERIVATIVEJanuary 2022March 2025Abandon3801NoNo
17628424HAIR TREATMENT COMPOSITION, METHOD FOR OBTAINING SAME, USE OF THE COMPOSITION AND HAIR TREATMENT METHODJanuary 2022April 2025Abandon3810NoNo
17628356HAIR CARE COMPOSITIONJanuary 2022December 2024Allow3510NoNo
17424622PHARMACEUTICAL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOFJanuary 2022March 2025Abandon4401NoNo
17597290ANTIBACTERIAL ARTICLE COMPRISING A POLYMER MATRIX WITH ALIGNED NANOSCALE FLAKES OR PLATELETSDecember 2021March 2025Abandon3801NoNo
17562690METHOD AND APPARATUS FOR TREATING BONE FRACTURES, AND/OR FOR FORTIFYING AND/OR AUGMENTING BONE, INCLUDING THE PROVISION AND USE OF COMPOSITE IMPLANTS, AND NOVEL COMPOSITE STRUCTURES WHICH MAY BE USED FOR MEDICAL AND NON-MEDICAL APPLICATIONSDecember 2021June 2023Abandon1810NoNo
17623171TRANSDERMAL DRUG DELIVERY PATCH, DRUG DELIVERY SYSTEM AND DRUG DELIVERY METHODDecember 2021April 2025Allow4011YesNo
17558763Multiple Unit Dosage Form Having A Therapeutic Agent In Combination With A Nutritional SupplementDecember 2021September 2023Allow2020NoNo
17619594RHODOSPIRILLUM RUBRUM CELLS THAT LOWER PLASMA CHOLESTEROL WHILE LEAVING OTHER SERUM PROTEIN LEVELS UNAFFECTEDDecember 2021March 2025Abandon3910NoNo
17553613SURFACE-REACTED CALCIUM CARBONATE IN FOODDecember 2021October 2023Allow2210YesNo
17548849Pharmaceutical Combination for the Treatment of CancerDecember 2021October 2023Allow2320YesNo
17596426FORMULATION FOR ODONTOLOGICAL AND DERMATOLOGICAL USE CONTAINING TRCHLOROACETATE SALTS AND HYDROXYACIDSDecember 2021August 2024Allow3210NoNo
17643046LIQUID COLLAGEN BIOINKS AND METHODS TO MAKE AND USE COLLAGEN STRUCTURESDecember 2021July 2024Allow3211NoNo
17614774COMPOSITION FOR FORMING COATING FILMNovember 2021January 2025Allow3810NoNo
17536674AQUEOUS COMPOSITION FOR LIVESTOCK ANIMALSNovember 2021August 2023Abandon2120NoNo
17529180PAINLESS NGF FOR FRACTURE REPAIRNovember 2021April 2024Abandon2910NoNo
176102422(1H)-PYRIDINONES AND THEIR USE TO TREAT INFLAMMATORY CONDITIONSNovember 2021September 2024Allow3510NoNo
17522358PETROLATUM SUBSTITUTION PREPARATIONNovember 2021December 2023Allow2510NoNo
17522727HYDROGELS FORMED IN SITU AND COMPOSITION DESIGN FOR INTRAUTERINE USENovember 2021March 2025Allow4021YesNo
17509037DRY POWDER FORMULATIONS FOR INHALATIONOctober 2021May 2023Abandon1810NoNo
17503965PET SUPPLEMENTS CONTAINING A CANNABINOIDOctober 2021February 2024Abandon2810NoNo
17499242ANTIMICROBIAL THIOURONIUM COPOLYMERS AND METHODS OF MAKING AND USING THE SAMEOctober 2021February 2024Allow2811NoNo
17601120COLLOIDAL SILVER-BASED COMPOSITIONS AND METHODS OF USE THEREOF FOR PREVENTING AND CONTROLLING PLANT DISEASESOctober 2021July 2024Allow3400NoNo
17488650CANNABINOID CHEWING GUM WITH SUGAR ALCOHOLSSeptember 2021July 2023Allow2220NoNo
17488492Alcohol Metabolism Acceleration CompositionSeptember 2021December 2023Allow2710YesNo
17599761TOPICAL COMPOSITIONSeptember 2021February 2025Allow4110YesNo
17483468TREATMENT OF COGNITIVE DYSFUNCTION WITH PYRROLOPYRIDINE-ANILINE COMPOUNDSSeptember 2021June 2024Abandon3311NoNo
17481263BIOMASS-BASED ENCAPSULATING MATERIAL FOR PROTECTION OF PROBIOTIC ACTIVITY AND AN ENCAPSULATING METHODSeptember 2021December 2023Allow2610YesNo
17593576DENTAL ADDITION SILICONE COMPOSITIONSeptember 2021January 2025Abandon4010NoNo
17440703METHOD FOR DYEING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, AN EFFECT PIGMENT AND A FILM-FORMING POLYMER IISeptember 2021April 2025Allow4321NoNo
17438886CAPSULE SHELL COMPRISING A CORE-SHELL POLYMER AND A CELLULOSESeptember 2021October 2023Allow2610YesNo
17436036METHOD FOR PREPARING AND USING HAIR TREATMENT AGENTS WITH ORGANIC C1-C6-ALKOXY-SILANESSeptember 2021December 2024Abandon3901NoNo
17463343SUBSTRATES FOR VAPORIZING AND DELIVERING AN AEROSOLAugust 2021October 2022Allow1331YesNo
17401542SCAFFOLDS FROM SELF-ASSEMBLING TETRAPEPTIDES SUPPORT 3D SPREADING, OSTEOGENIC DIFFERENTIATION AND ANGIOGENESIS OF MESENCHYMAL STEM CELLSAugust 2021June 2024Allow3411YesNo
17429045SURGICAL HYDROGELAugust 2021March 2025Abandon4311NoNo
17379351Mineral Coated Microparticles for Co-Delivery of Anti-Inflammatory Molecules with Nucleic Acids to Improve Gene Delivery OutcomesJuly 2021June 2023Allow2320YesNo
17290565PEPTIDE FOR PROMOTING MUCOUS MEMBRANE PERMEATION AND COMPOSITION CONTAINING SAMEJuly 2021April 2024Allow3511YesNo
17372773Hydrogel CompositionsJuly 2021December 2023Abandon2910NoNo
17351758POROUS SILICATE/MAGNETIC FERRITE NANOCARRIER FOR COMBINATION ANTI-CANCER THERAPEUTIC AND ANTIOXIDANT DELIVERYJune 2021August 2023Allow2611YesNo
17351190COMPARTMENTED HARD SHELL CAPSULE AND APPARATUS AND METHOD FOR FORMING, FILLING, AND ENCAPSULATING A COMPARTMENTED HARD SHELL CAPSULEJune 2021January 2024Abandon3121YesNo
17350356Personalized Medicament Delivery ProductJune 2021February 2024Abandon3220NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FUBARA, BLESSING M.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
32
Examiner Affirmed
18
(56.2%)
Examiner Reversed
14
(43.8%)
Reversal Percentile
65.7%
Higher than average

What This Means

With a 43.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
175
Allowed After Appeal Filing
46
(26.3%)
Not Allowed After Appeal Filing
129
(73.7%)
Filing Benefit Percentile
35.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 26.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner FUBARA, BLESSING M - Prosecution Strategy Guide

Executive Summary

Examiner FUBARA, BLESSING M works in Art Unit 1613 and has examined 1,154 patent applications in our dataset. With an allowance rate of 67.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.

Allowance Patterns

Examiner FUBARA, BLESSING M's allowance rate of 67.2% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by FUBARA, BLESSING M receive 2.21 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by FUBARA, BLESSING M is 27 months. This places the examiner in the 55% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +35.9% benefit to allowance rate for applications examined by FUBARA, BLESSING M. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 21.5% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 40.5% of cases where such amendments are filed. This entry rate is in the 54% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 93.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 67% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 74.0% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 53.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 61.5% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.5% of allowed cases (in the 73% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.1% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.